Literature DB >> 33594271

First-line infliximab for children with Crohn's disease.

Jordan Hindson1.   

Abstract

Entities:  

Year:  2021        PMID： 33594271     DOI： 10.1038/s41575-021-00429-1

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.

Authors:  Maria M E Jongsma; Martine A Aardoom; Martinus A Cozijnsen; Merel van Pieterson; Tim de Meij; Michael Groeneweg; Obbe F Norbruis; Victorien M Wolters; Herbert M van Wering; Iva Hojsak; Kaija-Leena Kolho; Thalia Hummel; Janneke Stapelbroek; Cathelijne van der Feen; Patrick F van Rheenen; Michiel P van Wijk; Sarah T A Teklenburg-Roord; Marco W J Schreurs; Dimitris Rizopoulos; Michail Doukas; Johanna C Escher; Janneke N Samsom; Lissy de Ridder
Journal:  Gut       Date:  2020-12-31       Impact factor: 23.059
  1 in total
  1 in total

Review 1.  Therapy Strategies for Children Suffering from Inflammatory Bowel Disease (IBD)-A Narrative Review.

Authors:  Corinne Légeret; Raoul Furlano; Henrik Köhler
Journal:  Children (Basel)       Date:  2022-04-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.